Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
About this Publication
Title
Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Pubmed ID
35365600
(View this publication on the PubMed website)
Digital Object Identifier
Publication
Blood Cancer J. 2022 Apr 1; Volume 12 (Issue 4): Pages 51
Authors
Chang VC, Khan AA, Huang WY, Katki HA, Purdue MP, Landgren O, Hofmann JN
Affiliations
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. chidan.chang@nih.gov.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
- Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Abstract
N/A
Related CDAS Studies
Related CDAS Projects
- PLCO-355: Evaluating circulating immunologic markers in the development of multiple myeloma (Jonathan Hofmann - 2018)